Rationale of concurrent Docetaxel Chemotherapy and radiation to chest wall & peripheral lymphatics after four cycles of AC chemotherapy in patients with early Breast Cancer

Authors

  • Shaharyar Abid Jamil
  • Ijaz Hussain Shah
  • Khalid Shabbir
  • Ahmed I Masood
  • Muhammad Hafeez
  • Abrar A Javed
  • Shaheena Perveen
  • Shahid A
  • Murad S
  • Randhawa I
  • Rasool S

DOI:

https://doi.org/10.21649/akemu.v12i4.970

Keywords:

Taxoids. Breast Cancer. Paclitaxel. Clinical Protocols. Antineoplastic Combined Chemotherapy Protocols. Neoadjuvant Therapy. Chest Wall. Cyclophosphamide. Doxorubicin.

Abstract

The Cancer Research Group Pakistan has started this phase II study with the objectives to assess the feasibility of this regimen. Recently, docetaxel has emerged as the most powerful cytotoxic drug against breast cancer. As a single agent in second line treatment in phase II trials in metastatic breast cancer, it has achieved a response rate of 53-58% at a dose of 100 mg/m2 given every three weeks.

Published

2016-04-05

How to Cite

Jamil, S. A., Shah, I. H., Shabbir, K., I Masood, A., Hafeez, M., A Javed, A., Perveen, S., A, S., S, M., I, R., & S, R. (2016). Rationale of concurrent Docetaxel Chemotherapy and radiation to chest wall & peripheral lymphatics after four cycles of AC chemotherapy in patients with early Breast Cancer. Annals of King Edward Medical University, 12(4). https://doi.org/10.21649/akemu.v12i4.970

Issue

Section

Articles